Vreman H J, Hintz S R, Kim C B, Castillo R O, Stevenson D K
Department of Pediatrics, Stanford University School of Medicine, California 94305.
J Pediatr Gastroenterol Nutr. 1988 Nov-Dec;7(6):902-6. doi: 10.1097/00005176-198811000-00019.
The purpose of this study was to investigate if oral metalloporphyrin treatment could suppress intestinal heme oxygenase (HO) activity and thus prevent HO-mediated heme degradation in this organ. Six hours after a single 40 mumol/kg oral dose of tin protoporphyrin (TP), zinc protoporphyrin (ZP), or heme to adult rats, no significant difference in the HO activity of the intestine was observed relative to control tissues. Moreover, the activity was not inhibited by in vitro exposure to 40 microM TP or ZP. Liver and spleen HO activity was also not significantly inhibited in vivo after oral administration of metalloporphyrins; however, in vitro exposure to TP or ZP decreased the HO activity of preparations from these organs significantly. Like adults, the intestinal HO activity of neonates was not inhibited effectively by oral administration of either metalloporphyrin. The results of subsequent in vitro exposure of control neonatal tissue preparations to ZP or TP was similar to those using adult tissue preparations. Even at 100 microM, only ZP seemed to have some in vitro inhibitory effect on the intestinal HO of suckling rats. We conclude that intestinal HO is less inhibitable by TP or ZP reaching the intestine via the stomach in concentrations at least 30-fold greater than those achieved after parenteral 40 mumol/kg doses, which cause significant hepatic and splenic HO inhibition. Intestinal absorption and enterohepatic circulation of heme, TP, and ZP do not seem to occur in amounts sufficient to consistently and significantly affect HO activity in liver or spleen.
本研究的目的是调查口服金属卟啉治疗是否能抑制肠道血红素加氧酶(HO)活性,从而防止该器官中HO介导的血红素降解。给成年大鼠单次口服40 μmol/kg的锡原卟啉(TP)、锌原卟啉(ZP)或血红素6小时后,相对于对照组织,未观察到肠道HO活性有显著差异。此外,体外暴露于40 μM的TP或ZP并未抑制该活性。口服金属卟啉后,肝脏和脾脏的HO活性在体内也未受到显著抑制;然而,体外暴露于TP或ZP可显著降低这些器官制剂的HO活性。与成年大鼠一样,新生大鼠口服任何一种金属卟啉均不能有效抑制肠道HO活性。随后将对照新生组织制剂体外暴露于ZP或TP的结果与使用成年组织制剂的结果相似。即使在100 μM时,似乎只有ZP对乳鼠肠道HO有一定的体外抑制作用。我们得出结论,通过胃进入肠道的TP或ZP对肠道HO的抑制作用较小,其浓度至少比静脉注射40 μmol/kg剂量后高30倍,后者可显著抑制肝脏和脾脏的HO活性。血红素、TP和ZP的肠道吸收及肠肝循环量似乎不足以持续且显著地影响肝脏或脾脏中的HO活性。